Clayton Lau, MD, on How COVID-19 Has and Will Continue to Impact Cancer Care
The chief of urologic oncology at City of Hope spoke about how the COVID-19 pandemic has altered the way he cares for patients with cancer as well as how he believes it will continue to impact cancer prevention, detection, and treatment moving forward.
Numerous studies have been published recently highlighting the impact that the coronavirus disease 2019 (COVID-19) pandemic has had on cancer prevention, detection, and treatment.
Though it is not yet known what the full impact of the pandemic will be, these studies emphasize concerns that delays in care could result in a rise of late-stage diagnoses and cancer deaths in the coming years.
In an interview with CancerNetwork®, Clayton Lau, MD, chief of urologic oncology at City of Hope, discussed how COVID-19 has affected his ability to treat patients with cancer as well as how he believes the pandemic will continue to shape cancer care.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
![Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F55a279b707f0cd71181a5efa8b3d3cd864555701-3002x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].")
